Drugs / ChAd63 CS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01450280 | Dec 2011 → Oct 2012 | malaria | University of Oxford | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT01739036 Comparator | Jan → Oct 2013 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT01623557 Comparator | Apr → Nov 2012 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAd63 CS | “1 dose of ChAd63 CS 5 x 10\^10 vp intramuscularly and 1 dose MVA CS 2 x 10\^8 pfu intramuscularly 8 weeks later.” NCT01623557 ↗ |
| Known as | AdCh63 CS | “This is an open label phase I study, to assess the safety of a novel malaria vaccine, AdCh63 CS, simian adenovirus encoding Plasmodium falciparum liver stage antigen,...” NCT01450280 ↗ |
| Modality | Vaccine | “the chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) replication-deficient viral vectored vaccines encoding the circumsporozoite protein (CS) of P. falciparum.” PMID 25522180 ↗ Dec 2014 |
| Route | Intramuscular | “They will be primed with various doses of AdCh63 CS administered intramuscularly.” NCT01450280 ↗ |